US Grants Priority Review for Shire’s Lifitegrast Dry Eye Treatment

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Shire for its lifitegrast dry eye treatment for adults and has designated it as a Priority Review. If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of the disease.

The FDA is expected to give a decision on 25 October 2015. Priority Review designation, which is granted to drugs with the potential to significantly improve the safety or effectiveness for the treatment, diagnosis or prevention of a serious disease, have an accelerated review target of eight months, instead of the standard 12 months.

"Our NDA filing for lifitegrast represents an important regulatory milestone, exemplifying Shire's ability to forge new paths in therapeutic areas aligned with our focus in rare and specialty conditions," said Philip J Vickers, Shire's head of research and development. He added: "Our commitment to moving lifitegrast forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need."

Dry eye is a progressive and often chronic disease and one of the most common complaints for professionals treating ocular conditions.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.